Licochalcone E activates Nrf2/antioxidant response element signaling pathway in both neuronal and microglial cells: Therapeutic relevance to neurodegenerative disease

Journal of Nutritional Biochemistry

Volumn 23, Issue 10, 2012, Pages 1314-1323

  Kim, Sa Suk ^a   Lim, Juhee ^a   Bang, Yeojin ^a   Gal, Jiyeong ^a   Lee, Sang Uk ^a   Cho, Young Chang ^a   Yoon, Goo ^b   Kang, Bok Yun ^a   Cheon, Seung Hoon ^a   Choi, Hyun Jin ^a  

^a Chonnam National University   (South Korea)

^b Mokpo National University   (South Korea)

Author keywords

HO 1; Licochalcone E; Neuroprotection; NQO1; Nrf2; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ANTIINFLAMMATORY AGENT; DEXAMETHASONE; GLYCYRRHIZA EXTRACT; HEME OXYGENASE 1; LICOCHALCONE E; LIPOPOLYSACCHARIDE; NITRITE REDUCTASE [NAD(P)H]; OXIDOPAMINE; OXYGENASE INHIBITOR; QUINONE DERIVATIVE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT RESPONSIVE ELEMENT; ARTICLE; CELL PROTECTION; CONTROLLED STUDY; CYTOTOXICITY; DOPAMINERGIC NERVE CELL; GENE SILENCING; GLYCYRRHIZA; GLYCYRRHIZA INFLATA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MICROGLIA; MOUSE; NERVE CELL; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; SIGNAL TRANSDUCTION; STRIATONIGRAL DEGENERATION; SUBSTANTIA NIGRA; UPREGULATION;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANT RESPONSE ELEMENTS; CELL LINE; CHALCONES; CYTOPROTECTION; DOPAMINE; GENES, REPORTER; HEK293 CELLS; HEME OXYGENASE-1; HUMANS; LIPOPOLYSACCHARIDES; MICE; MICROGLIA; NAD(P)H DEHYDROGENASE (QUINONE); NEURODEGENERATIVE DISEASES; NEURONS; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; OXIDOPAMINE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; UP-REGULATION;

GLYCYRRHIZA INFLATA; MUS;

EID: 84865499490     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2011.07.012     Document Type: Article

References (50)

1. Dawson T., Dawson V. Molecular pathways of neurodegeneration in Parkinson's disease. Science 2003, 302:819-822.
2. Tansey M., Frank-Cannon T., McCoy M., Lee J., Martinez T., McAlpine F., et al. Neuroinflammation in Parkinson's disease: is there sufficient evidence for mechanism-based interventional therapy?. Front Biosci 2008, 13:709-717.
3. No H., Bang Y., Lim J., Kim S., Choi H., Choi H. Involvement of induction and mitochondrial targeting of orphan nuclear receptor Nur77 in 6-OHDA-induced SH-SY5Y cell death. Neurochem Int 2010, 56:620-626.
4. Offen D., Ziv I., Sternin H., Melamed E., Hochman A. Prevention of dopamine-induced cell death by thiol antioxidants: possible implications for treatment of Parkinson's disease. Exp Neurol 1996, 141:32-39.
5. Hastings T., Lewis D., Zigmond M. Reactive dopamine metabolites and neurotoxicity: implications for Parkinson's disease. Adv Exp Med Biol 1996, 387:97-106.
6. Choi H.J., Kim S.W., Lee S.Y., Hwang O. Dopamine-dependent cytotoxicity of tetrahydrobiopterin: a possible mechanism for selective neurodegeneration in Parkinson's disease. J Neurochem 2003, 86:143-152.
7. Chae S., Bang Y., Kim K., Lee K., Kang B., Kim E., et al. Role of cyclooxygenase-2 in tetrahydrobiopterin-induced dopamine oxidation. Biochem Biophys Res Commun 2007, 359:735-741.
8. Müller T., Blum-Degen D., Przuntek H., Kuhn W. Interleukin-6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson's disease. Acta Neurol Scand 1998, 98:142-144.
9. Whitton P. Inflammation as a causative factor in the aetiology of Parkinson's disease. Br J Pharmacol 2007, 150:963-976.
10. Knott C., Stern G., Wilkin G. Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2. Mol Cell Neurosci 2000, 16:724-739.
11. Nioi P., Hayes J. Contribution of NAD(P)H:quinone oxidoreductase 1 to protection against carcinogenesis, and regulation of its gene by the Nrf2 basic-region leucine zipper and the arylhydrocarbon receptor basic helix-loop-helix transcription factors. Mutat Res 2004, 555:149-171.
12. Talalay P., Dinkova-Kostova A. Role of nicotinamide quinone oxidoreductase 1 (NQO1) in protection against toxicity of electrophiles and reactive oxygen intermediates. Methods Enzymol 2004, 382:355-364.
13. Owuor E., Kong A. Antioxidants and oxidants regulated signal transduction pathways. Biochem Pharmacol 2002, 64:765-770.
14. Prawan A., Kundu J., Surh Y. Molecular basis of heme oxygenase-1 induction: implications for chemoprevention and chemoprotection. Antioxid Redox Signal 2005, 7:1688-1703.
15. Lehmann J., Listopad J., Rentzsch C., Igney F., von Bonin A., Hennekes H., et al. Dimethylfumarate induces immunosuppression via glutathione depletion and subsequent induction of heme oxygenase 1. J Invest Dermatol 2007, 127:835-845.
16. Kolbe L., Immeyer J., Batzer J., Wensorra U., tom Dieck K., Mundt C., et al. Anti-inflammatory efficacy of licochalcone A: correlation of clinical potency and in vitro effects. Arch Dermatol Res 2006, 298:23-30.
17. Haraguchi H., Ishikawa H., Mizutani K., Tamura Y., Kinoshita T. Antioxidative and superoxide scavenging activities of retrochalcones in Glycyrrhiza inflata. Bioorg Med Chem 1998, 6:339-347.
18. Yoon G., Kang B., Cheon S. Topoisomerase I inhibition and cytotoxicity of licochalcones A and E from Glycyrrhiza inflata. Arch Pharm Res 2007, 30:313-316.
19. Saitoh T., Shibata S. New type chalcones from licorice root. Tetrahedron Lett 1975, 16:4461-4462.
20. Yoon G., Jung Y., Cheon S. Cytotoxic allyl retrochalcone from the roots of Glycyrrhiza inflata. Chem Pharm Bull (Tokyo) 2005, 53:694-695.
21. Cho Y., Lee S., Yoon G., Kim H., Na J., Choi H., et al. Licochalcone E reduces chronic allergic contact dermatitis and inhibits IL-12p40 production through down-regulation of NF-kappaB. Int Immunopharmacol 2010, 10:1119-1126.
22. Foresti R., Hoque M., Monti D., Green C., Motterlini R. Differential activation of heme oxygenase-1 by chalcones and rosolic acid in endothelial cells. J Pharmacol Exp Ther 2005, 312:686-693.
23. Perjési P., Ember I., Bozak R., Nádasi E., Rozmer Z., Varjas T., et al. Effect of the chalcone analog E,E-bis(2-hydroxybenzylidene) acetone on the 7,12-dimethylbenz[a]anthracene-induced Ha-ras gene activity in vivo. In Vivo 2006, 20:141-146.
24. Lim J., Kim K., Kim S., Hwang O., Choi H. Bromocriptine activates NQO1 via Nrf2-PI3K/Akt signaling: novel cytoprotective mechanism against oxidative damage. Pharmacol Res 2008, 57:325-331.
25. Kang K., Cho I., Lee C., Kim S. Essential role of phosphatidylinositol 3-kinase-dependent CCAAT/enhancer binding protein beta activation in the induction of glutathione S-transferase by oltipraz. J Natl Cancer Inst 2003, 95:53-66.
26. Cui Y., Ao M., Li W., Hu J., Yu L. Anti-inflammatory activity of licochalcone A isolated from Glycyrrhiza inflata. Z Naturforsch C 2008, 63:361-365.
27. Thomas D., Francescutti-Verbeem D., Kuhn D. Gene expression profile of activated microglia under conditions associated with dopamine neuronal damage. FASEB J 2006, 20:515-517.
28. Alcaraz M., Vicente A., Araico A., Dominguez J., Terencio M., Ferrándiz M. Role of nuclear factor-kappaB and heme oxygenase-1 in the mechanism of action of an anti-inflammatory chalcone derivative in RAW 264.7 cells. Br J Pharmacol 2004, 142:1191-1199.
29. Moncada S., Higgs A. The l-arginine-nitric oxide pathway. N Engl J Med 1993, 329:2002-2012.
30. Radomski M., Palmer R., Moncada S. Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc Natl Acad Sci U S A 1990, 87:10043-10047.
31. New type chalcones from licorice root. Tetrahedron Letters. 1975;16:4461-2.
32. Syapin P. Regulation of haeme oxygenase-1 for treatment of neuroinflammation and brain disorders. Br J Pharmacol 2008, 155:623-640.
33. Członkowska A., Kohutnicka M., Kurkowska-Jastrzebska I., Członkowski A. Microglial reaction in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induced Parkinson's disease mice model. Neurodegeneration 1996, 5:137-143.
34. Jackson-Lewis V., Smeyne R. MPTP and SNpc DA neuronal vulnerability: role of dopamine, superoxide and nitric oxide in neurotoxicity. Mini Rev Neurotox Res 2005, 7:193-202.
35. Chen P., Vargas M., Pani A., Smeyne R., Johnson D., Kan Y., et al. Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: critical role for the astrocyte. Proc Natl Acad Sci U S A 2009, 106:2933-2938.
36. Herencia F., Ferrándiz M., Ubeda A., Domínguez J., Charris J., Lobo G., et al. Synthesis and anti-inflammatory activity of chalcone derivatives. Bioorg Med Chem Lett 1998, 8:1169-1174.
37. Furusawa J., Funakoshi-Tago M., Tago K., Mashino T., Inoue H., Sonoda Y., et al. Licochalcone A significantly suppresses LPS signaling pathway through the inhibition of NF-kappaB p65 phosphorylation at serine 276. Cell Signal 2009, 21:778-785.
38. Furusawa J., Funakoshi-Tago M., Mashino T., Tago K., Inoue H., Sonoda Y., et al. Glycyrrhiza inflata-derived chalcones, licochalcone A, licochalcone B and licochalcone D, inhibit phosphorylation of NF-kappaB p65 in LPS signaling pathway. Int Immunopharmacol 2009, 9:499-507.
39. Pawate S., Shen Q., Fan F., Bhat N. Redox regulation of glial inflammatory response to lipopolysaccharide and interferongamma. J Neurosci Res 2004, 77:540-551.
40. Wu C., Hsu M., Hsieh C., Lin J., Lai P., Wung B. Upregulation of heme oxygenase-1 by Epigallocatechin-3-gallate via the phosphatidylinositol 3-kinase/Akt and ERK pathways. Life Sci 2006, 78:2889-2897.
41. Juan M., González-Pons E., Munuera T., Ballester J., Rodríguez-Gil J., Planas J. trans-Resveratrol, a natural antioxidant from grapes, increases sperm output in healthy rats. J Nutr 2005, 135:757-760.
42. Lim J., Park H., Choi J., Lee I., Choi H. Isoorientin induces Nrf2 pathway-driven antioxidant response through phosphatidylinositol 3-kinase signaling. Arch Pharm Res 2007, 30:1590-1598.
43. Wu R., Hayashi T., Cottam H., Jin G., Yao S., Wu C., et al. Nrf2 responses and the therapeutic selectivity of electrophilic compounds in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2010, 107:7479-7484.
44. Dinkova-Kostova A., Massiah M., Bozak R., Hicks R., Talalay P. Potency of Michael reaction acceptors as inducers of enzymes that protect against carcinogenesis depends on their reactivity with sulfhydryl groups. Proc Natl Acad Sci U S A 2001, 98:3404-3409.
45. Liu Y., Hsieh C., Wu C., Wung B. Chalcone inhibits the activation of NF-kappaB and STAT3 in endothelial cells via endogenous electrophile. Life Sci 2007, 80:1420-1430.
46. Ramsey C., Glass C., Montgomery M., Lindl K., Ritson G., Chia L., et al. Expression of Nrf2 in neurodegenerative diseases. J Neuropathol Exp Neurol 2007, 66:75-85.
47. Burton N., Kensler T., Guilarte T. In vivo modulation of the Parkinsonian phenotype by Nrf2. Neurotoxicology 2006, 27:1094-1100.
48. Jakel R., Townsend J., Kraft A., Johnson J. Nrf2-mediated protection against 6-hydroxydopamine. Brain Res 2007, 1144:192-201.
49. Calkins M., Jakel R., Johnson D., Chan K., Kan Y., Johnson J. Protection from mitochondrial complex II inhibition in vitro and in vivo by Nrf2-mediated transcription. Proc Natl Acad Sci U S A 2005, 102:244-249.
50. Hansch C., Björkroth J., Leo A. Hydrophobicity and central nervous system agents: on the principle of minimal hydrophobicity in drug design. J Pharm Sci 1987, 76:663-687.